Subclinical nephrotoxicity in patients with beta-thalassemia: role of urinary kidney injury molecule

We aimed to investigate the role of urinary kidney injury molecule-1 (KIM-1) in detection of subclinical nephrotoxicity in patients with Beta-thalassemia (β-TM) in relation to chelation therapy and to correlate the urinary KIM-1 level with other clinical and laboratory findings. We conducted a cross...

Full description

Saved in:
Bibliographic Details
Published in:Drug and chemical toxicology (New York, N.Y. 1978) N.Y. 1978), 2022-01, Vol.45 (1), p.93-102
Main Authors: Nafea, Ola E., Zakaria, Marwa, Hassan, Tamer, El Gebaly, Sherif M., Salah, Hosam E.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Beta-thalassemia
beta-Thalassemia - complications
beta-Thalassemia - drug therapy
chelation
Child
Cross-Sectional Studies
Deferasirox
Deferoxamine - adverse effects
Humans
Iron Chelating Agents - adverse effects
Iron Overload
Kidney
KIM-1
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to investigate the role of urinary kidney injury molecule-1 (KIM-1) in detection of subclinical nephrotoxicity in patients with Beta-thalassemia (β-TM) in relation to chelation therapy and to correlate the urinary KIM-1 level with other clinical and laboratory findings. We conducted a cross-sectional study on 66 thalassemic patients. Their ages range from 7 to 22 years. Routine kidney indices and novel urinary KIM/creatinine ratio (U KIM-1/Cr ) were measured. Estimated glomerular filtration rate (eGFR) was calculated. Results indicate that the level of serum creatinine was significantly higher in patients on deferasirox therapy than patients on deferoxamine and deferiprone therapy [median(IQR), 0.85(0.63-0.99), 0.50(0.34-0.58) and 0.44(0.36-0.45)] mg/dL, respectively, p 
ISSN:0148-0545
1525-6014
DOI:10.1080/01480545.2019.1660362